Evecxia Therapeutics, Inc.

📍 Research Triangle Park, United States🗓 Founded 2013👥 6 employees💰 Last funded Dec 2025
Biotechnology🌐 evecxia.com
Website LinkedIn
Evecxia is the first company dedicated to realizing the therapeutic potential of amplifying serotonin synthesis to treat brain disorders. Serotonin synthesis amplification is distinct from targeting serotonin transporters (e.g., SSRIs) and receptors (e.g., psilocybin). Evecxia deploys 5-HTP, the natural serotonin precursor, delivered via proprietary drug delivery technologies to achieve sustained serotonin synthesis amplification. Evecxia has two Phase 2 clinical-stage drug candidates in development. EVX-101 is being developed as an adjunctive treatment for depression when first-line SSRI/SNRI antidepressants alone are inadequate. EVX-301 is being developed as a rescue therapy for patients in acute suicidal ideation crisis. Evecxia holds a comprehensive portfolio of issued and pending patents on the 5-HTP sustained-release/serotonin amplification method, doses, formulations, and related technologies.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2013
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Evecxia Therapeutics, Inc.?
Evecxia Therapeutics, Inc. has 1 investors on record on gritt.io.
When did Evecxia Therapeutics, Inc. last raise funding?
The most recent investment in Evecxia Therapeutics, Inc. recorded on gritt.io was in December 2025.
When was Evecxia Therapeutics, Inc. founded?
Evecxia Therapeutics, Inc. was founded in 2013.
What industry is Evecxia Therapeutics, Inc. in?
Evecxia Therapeutics, Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Evecxia Therapeutics, Inc. based?
Evecxia Therapeutics, Inc. is headquartered in Research Triangle Park, United States.